Asia-Pacific biologics market is estimated to grow at a CAGR of 9.2% during the forecast period. Some pivotal factors accelerating market growth include the rising prevalence of cancer and increasing launches of biologics therapy. As per the World Health Organization (WHO), in Asia, the number of new cancer incidences expected to be reported in 2020 will be nearly 9.5 million. This, in turn, is leading to an increasing demand for biologics drugs which acts as an immune system substance that supports to augment the body’s ability to fight against cancer. Biologics comprises a comprehensive range of drugs that particularly target cancer cells, encourage the immune response, and support the recovery from cancer treatment. These drugs are normally utilized in combination with other therapies, including chemotherapy.

Visit for Global Biologics Market Report at: https://www.omrglobal.com/industry-reports/biologics-market

Asia-Pacific biologics market is segmented based on product and application. Based on the product, the market is segmented into antibody therapeutics, vaccines, cell therapy, gene therapy, and others. A large number of biologics available in the market are monoclonal antibodies and several products are in the pipeline. Over the decades, advances in the improvement of the humanization of monoclonal antibodies have been witnessed, which, in turn, improves efficacy and decreasing immunogenicity. Monoclonal antibodies are regarded as highly targeted drugs, binds to the cancerous cells, and poison the tumor to destroy it. One instance of a biological drug includes Trastuzumab, which is utilized in particular for metastatic breast cancer in women. Another instance is Rituxan, which is utilized to support the treatment of non-Hodgkin’s lymphoma. Based on application, the market is segmented into cancer, autoimmune diseases, infectious diseases, and others. 

Some key players operating in the market include AbbVie Inc., Eli Lilly and Co., F. Hoffman-La Roche AG, and Daiichi Sankyo Co., Ltd. The market players are focusing on strategic initiatives, to gain a significant market share. For instance, in November 2019, China’s Bio-Thera Solutions Ltd. gained regulatory approval for its AbbVie Inc’s blockbuster rheumatoid arthritis therapy Humira, which paves the way for the first such biosimilar to enter the world’s second-largest drug market. It has been approved to treat three autoimmune diseases, which include plaque psoriasis, rheumatoid arthritis, and ankylosing spondylitis. The approval of this drug will offer a new affordable treatment alternative for patients in China suffering from several kinds of autoimmune diseases. 

Research Methodology

The market study of the Asia-Pacific biologics market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Asia-Pacific Biologics Market Research and Analysis by Product
2. Asia-Pacific Biologics Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the Asia-Pacific biologics market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the Asia-Pacific biologics market.
• Insights about market determinants which are stimulating the Asia-Pacific biologics market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.